668 related articles for article (PubMed ID: 25854553)
1. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
[TBL] [Abstract][Full Text] [Related]
3. Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection.
Wang Q; Chen S; Xiao Q; Liu Z; Liu S; Hou P; Zhou L; Hou W; Ho W; Li C; Wu L; Guo D
Retrovirology; 2017 Nov; 14(1):51. PubMed ID: 29141633
[TBL] [Abstract][Full Text] [Related]
4. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection.
Wang W; Ye C; Liu J; Zhang D; Kimata JT; Zhou P
PLoS One; 2014; 9(12):e115987. PubMed ID: 25541967
[TBL] [Abstract][Full Text] [Related]
5. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
[TBL] [Abstract][Full Text] [Related]
7. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing.
Kaminski R; Chen Y; Fischer T; Tedaldi E; Napoli A; Zhang Y; Karn J; Hu W; Khalili K
Sci Rep; 2016 Mar; 6():22555. PubMed ID: 26939770
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
[TBL] [Abstract][Full Text] [Related]
9. G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates.
Amara A; Vidy A; Boulla G; Mollier K; Garcia-Perez J; Alcamí J; Blanpain C; Parmentier M; Virelizier JL; Charneau P; Arenzana-Seisdedos F
J Virol; 2003 Feb; 77(4):2550-8. PubMed ID: 12551993
[TBL] [Abstract][Full Text] [Related]
10. Biallelic, Selectable, Knock-in Targeting of CCR5
Scheller SH; Rashad Y; Saleh FM; Willingham KA; Reilich A; Lin D; Izadpanah R; Alt EU; Braun SE
Front Immunol; 2022; 13():821190. PubMed ID: 35386712
[TBL] [Abstract][Full Text] [Related]
11. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4
Liu Z; Chen S; Jin X; Wang Q; Yang K; Li C; Xiao Q; Hou P; Liu S; Wu S; Hou W; Xiong Y; Kong C; Zhao X; Wu L; Li C; Sun G; Guo D
Cell Biosci; 2017; 7():47. PubMed ID: 28904745
[TBL] [Abstract][Full Text] [Related]
12. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection.
Hou P; Chen S; Wang S; Yu X; Chen Y; Jiang M; Zhuang K; Ho W; Hou W; Huang J; Guo D
Sci Rep; 2015 Oct; 5():15577. PubMed ID: 26481100
[TBL] [Abstract][Full Text] [Related]
13. Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells.
Agrawal L; Lu X; Qingwen J; VanHorn-Ali Z; Nicolescu IV; McDermott DH; Murphy PM; Alkhatib G
J Virol; 2004 Mar; 78(5):2277-87. PubMed ID: 14963124
[TBL] [Abstract][Full Text] [Related]
14. Increased Efficiency for Biallelic Mutations of the
Lin D; Scheller SH; Robinson MM; Izadpanah R; Alt EU; Braun SE
CRISPR J; 2021 Feb; 4(1):92-103. PubMed ID: 33616448
[TBL] [Abstract][Full Text] [Related]
15. Improved Cas9 activity by specific modifications of the tracrRNA.
Scott T; Urak R; Soemardy C; Morris KV
Sci Rep; 2019 Nov; 9(1):16104. PubMed ID: 31695072
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.
Ehrke-Schulz E; Schiwon M; Leitner T; Dávid S; Bergmann T; Liu J; Ehrhardt A
Sci Rep; 2017 Dec; 7(1):17113. PubMed ID: 29215041
[TBL] [Abstract][Full Text] [Related]
17. The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.
Saifullah M; Laghzaoui O; Ozyahyalar H; Irfan A
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2430-2463. PubMed ID: 38567606
[TBL] [Abstract][Full Text] [Related]
18. Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing.
Knipping F; Newby GA; Eide CR; McElroy AN; Nielsen SC; Smith K; Fang Y; Cornu TI; Costa C; Gutierrez-Guerrero A; Bingea SP; Feser CJ; Steinbeck B; Hippen KL; Blazar BR; McCaffrey A; Mussolino C; Verhoeyen E; Tolar J; Liu DR; Osborn MJ
Mol Ther; 2022 Jan; 30(1):130-144. PubMed ID: 34737067
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts.
Cagnon L; Rossi JJ
Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):251-61. PubMed ID: 10984119
[TBL] [Abstract][Full Text] [Related]
20. A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells.
Hultquist JF; Schumann K; Woo JM; Manganaro L; McGregor MJ; Doudna J; Simon V; Krogan NJ; Marson A
Cell Rep; 2016 Oct; 17(5):1438-1452. PubMed ID: 27783955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
